Antibodies, The key to spatial mass spectrometry success
Event Date: October 5, 2021
In this webinar, join Dr. Mike Spencer, senior director of antibody validation and IHC at Fortis Life Sciences, as he explores effective strategies to ensure optimal antibody performance in multiplex IHC assays.
Multiplex immunohistochemistry (IHC) techniques allow multiple proteins to be visualized in the tissue leading to the identification of cell phenotypes, which can help gain an understanding of the spatial arrangement of cells within a tumor. Each multiplex IHC method places unique challenges upon antibody performance. For example, tyramide signal amplification (TSA)-based multiplex immunofluorescence assays (mIF) require optimization of staining order, while antibody performance can become compromised after metal conjugation during imaging mass spectrometry.
In this webinar, join Mike Spencer, senior director of antibody validation and IHC at Fortis Life Sciences, as he explores effective strategies to ensure optimal antibody performance in multiplex IHC assays.
Key learning objectives:
- Learn how poor antibody performance can impact multiplex IHC assay results
- Understand how different multiplex IHC platforms come with their own set of unique challenges
- Discover how to efficiently screen antibodies for imaging mass spectrometry
Speaker: Dr. Mike Spencer, Director of Immunohistochemistry and Digital Pathology
Dr. Mike Spencer received his doctorate in Molecular and Cellular Biochemistry from the University of Kentucky. The immunohistochemistry lab at Fortis Life Sciences validates the performance of new Bethyl antibody products in immunohistochemistry and immunocytochemistry applications.
Dr. Spencer has been integral in extending the capabilities of immunochemistry lab to include multiplex immunoassays for spatial biology.